Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Merus (Group)

Merus is a Dutch biotechnology company developing cancer therapeutics based on human bispecific antibodies. Merus’ bispecific antibodies have the robust and proven full-length IgG format, they are manufactured using industry standard processes and have predictable in vivo behavior such as long half-life and low immunogenicity. Merus has two lead programs in development, MCLA-128 for the treatment of HER2 expressing solid tumors, and MCLA-117 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company is also developing a broad pipeline of preclinical programs in immuno-oncology using its unique technology platforms. *


Period Start 2006-01-17 existent
  Today Merus B.V.
Products Industry Biclonics® antibody
  Industry 2 MeMo™ humanized mouse antibody platform
Persons Person Logtenberg, Ton (Merus BV 200601 CEO)
  Person 2 Crowley, John (Merus 201611– CFO based in US before Charles River + Vertex + Sunovian)
Region Region Utrecht
  Country Netherlands
Basic data Employees n. a.
  Currency EUR
  Annual sales 1,977,000 (revenue (2015) 2015-12-31)
  Profit -23,184,000 (2015-12-31)
  Cash 32,851,000 (2015-12-31)
    * Document for �About Section�: 
Record changed: 2021-04-01


Picture [iito] Made Without Love 650x80px

More documents for Merus (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top